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THERE’S A PILL FOR THAT!  STATE LAW APPROACHES 





In a hypothetical community the approximate size of South Bend, Indianapop-
ulation 100,000fourteen people die each year from an opioid overdose.1  About six 
of those deaths are attributed to prescription opioids.2  One in two citizens in the 
community who is prescribed drugs misuses them,3 and one in three citizens used 
prescription opioids in the past year, whether acquired through a doctor’s prescription 
or illegal means.4  These statistics are not merely illustrative: they approximate na-
tional data on what is known in modern parlance as the “opioid epidemic.”5   
The American fixation with opioids has been labeled a “public health emer-
gency”6 by the federal government.  Like crack cocaine and methamphetamine in 
                                                          
†   J.D. Candidate, University of Notre Dame Law School, 2019; B.S. in Health Science Studies with a 
Minor in Addiction Studies, Boise State University, 2012.  Thank you to the Journal of Legislation for pub-
lishing this piece.  I would like to extend my sincere gratitude to Professor Barbara Fick for the inspiration to 
write it and for guidance throughout the project.  Special thanks, also, to my writing guru – Grace Meikle – 
for her advice, and to my greatest advocate – Theodore Wunderlich – for his loyal support in all of my law 
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1   This calculation is based on the statistic that 130 Americans die every day from opioid overdose.  
Opioid Crisis, NAT’L INST. ON DRUG ABUSE (Jan. 2019), https://www.drugabuse.gov/drugs-abuse/opi-
oids/opioid-crisis. 
2   This calculation is based on the statistic that approximately forty percent of opioid-related deaths in 
2016 were attributed to prescription opioids.  About the Epidemic, U.S. DEP’T OF HEALTH & HUM. SERV’S. 
(Jan. 22, 2019), https://www.hhs.gov/opioids/about-the-epidemic/index.html. 
3   This calculation is based on the results of a study of 3.4 million drug monitoring lab results, which 
demonstrated that half of the individuals tested misused their prescription drugs.  Half of Americans Tested 
Misuse Their Prescription Medications, According to Quest Diagnostics Analysis, QUEST DIAGNOSTICS 
(Sept. 6, 2017), http://newsroom.questdiagnostics.com/2017-09-06-Half-of-Americans-Tested-Misuse-Their-
Prescription-Medications-According-to-Quest-Diagnostics-Analysis.  Misuse was defined in the study as tak-
ing prescribed drugs in a manner “inconsistent with [a] physician’s instructions.” Id.  
4   This calculation is based on the statistic that one in three Americans took prescription opioids in 
2015, which were most commonly obtained from a physician, friend, or relative.  Corky Siemaszko, One in 
Three Americans Took Prescription Opioid Painkillers in 2015, Survey Says, NBC NEWS (July 31, 2017), 
https://www.nbcnews.com/storyline/americas-heroin-epidemic/one-three-americans-took-prescription-opioid-
painkillers-2015-survey-says-n788246. 
5   See Marc Lewis, The Truth About the U.S. “Opioid Crisis” – Prescriptions Aren’t the Problem, THE 
GUARDIAN (Nov. 7, 2017), https://www.theguardian.com/commentisfree/2017/nov/07/truth-us-opioid-crisis-
too-easy-blame-doctors-not-prescriptions. 
6   Chris McGeal, Trump Declares Health Emergency Over Opioids but No New Funds to Help, THE 
GUARDIAN (Oct. 26, 2017), https://www.theguardian.com/us-news/2017/oct/26/trump-opioids-crisis-health-
emergency-funds. 
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prior decades, opioids are the “national scourge” of this day and age;7 but what ex-
actly are they?  Opioids belong to a class of drugs that reduces pain, including opiates 
(naturally-occurring opioids derived from the opium plant, such as heroin, morphine 
and codeine) and synthetic opioids, such as oxycodone (commonly, OxyContin), hy-
drocodone (commonly, Vicodin) and fentanyl.8  Neurobiologically, opioids reduce 
pain by binding to specialized proteins, called opioid receptors, in the brain.9  When 
opioids are misused, reward centers in the brain produce feelings of euphoria which, 
in the absence of pain, “can motivate repeated use of the drug simply for pleasure.”10  
In other words, opioids are both powerful and highly addictive. 
While heroin is illegal, many other opioids are routinely prescribed by doctors 
across the country11 to manage pain associated with chronic illness, surgery recovery, 
or serious injury.  Routine is perhaps an understatement: the United States dramati-
cally “outpaces” every other nation in the world in opioid consumption, consuming—
for example, “more than 99 percent” of the world’s supply of hydrocodone12—a pop-
ular prescription opioid.  In recent decades there has been an uptick in the “environ-
mental availability” of prescription opioids for the average American13 due to the 
heightened “social acceptability” of prescription opioid use for pain management and 
“aggressive marketing by pharmaceutical companies”14 to that end.  There has been 
a dramatic increase in the frequency with which opioids are prescribed by doctors to 
treat “chronic, non-cancer pain, such as back pain or osteoarthritis” in spite of the 
“serious risks and the lack of evidence about their long-term effectiveness”15 in such 
applications.  One scholar posits that cultural factors may “augment” opioid con-
sumption in the United States; whereas other cultures may accept pain as a product 
of “aging and physical decay,” “an achy American might demand that his doctor fix 
what he sees as an avoidable problem by prescribing him opioids.”16    
                                                          
7   V. John Ella & Craig W. Trepanier, Three Decades of DATWA, 74-SEP BENCH & BAR MINN. 14, 15 
(2017). 
8   Natural Opiates v. Synthetics: Are They as Dangerous?, OPIUM.ORG (2019), 
http://www.opium.org/natural-opiates-vs-synthetics-are-they-as-dangerous.html.  
9   Thomas R. Kosten & Tony P. George, The Neurobiology of Opioid Dependence: Implications for 
Treatment, 1 SCI. PRAC. PERSP. 13, 14 (2002), https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC2851054/pdf/spp-01-1-13.pdf.  
10  Id.  
11  See Yuki Noguchi, Opioid Abuse Takes a Toll on Workers and Their Employees, NPR (Jan. 20, 
2016), http://www.npr.org/sections/health-shots/2016/01/20/462922517/opioid-abuse-takes-a-toll-on-work-
ers-and-their-employers (explaining that “[h]ow often doctors choose (to prescribe prescription opioids) varies 
by state” with some evidence that doctors in Arkansas and Louisiana have the highest prescription rates).  
12  Keith Humphreys, Americans Use Far More Opioids Than Anyone Else in the World, WASH. POST 
(Mar. 15, 2017), https://www.washingtonpost.com/news/wonk/wp/2017/03/15/americans-use-far-more-opi-
oids-than-anyone-else-in-the-world/?utm_term=.dca789ea3cf2. 
13  Nora D. Volkow, America’s Addiction to Opioids: Heroin and Prescription Drug Abuse, NAT’L 
INST. ON DRUG ABUSE (May 14, 2014), https://www.drugabuse.gov/about-nida/legislative-activities/testi-
mony-to-congress/2016/americas-addiction-to-opioids-heroin-prescription-drug-abuse. 
14  Id.  
15  Prescription Opioids, CTR. FOR DISEASE CONTROL & PREVENTION (Aug. 29, 2017), 
https://www.cdc.gov/drugoverdose/opioids/prescribed.html. 
16  Humphreys, supra note 12. 
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Given that millions and millions of Americans suffer from chronic pain,17 it is 
not a surprise that many “achy American[s]”18 comprise the American workforce 
and that the prescription opioid epidemic has hit employers particularly hard.  Ac-
cording to a survey conducted by the National Safety Council (“NSC”), seven out of 
ten employers have felt “some effect” of prescription opioid use in the workplace, 
whether that be a positive employee drug test, decreased job performance, or some 
other consequence.19  Opioid abuse by employees costs employers $12 billion per 
year.20  This exorbitant figure comes, in part, from “higher [workers’] compensation 
costs,” “[higher] health insurance premiums,” and “increased employee turnover.”21  
According to the NSC, healthcare costs for employees who misuse prescription drugs 
“are three times higher than for an average employee.”22  All of that is just the tip of 
the iceberg: “liability for industrial accidents or product defects or workplace inju-
ries” involving prescription opioids add more still to the pool of potential costs to 
employers.23   
There has been substantial academic discussion and vigorous debate about the 
role that workplace drug testing can play in addressing employer concerns with re-
spect to employee drug use, generally.  After all, employers need a way to protect 
their businesses from the potentially harmful consequences of employee drug use.  
Employees, however, have an interest in preventing unnecessary interference with 
their personal lives, recreational activities, and/or medical needs24: interests that are 
at least as compelling as their employers’.  This Note adds to the existing discussion 
on workplace drug testing with an analysis of the unique policy challenges posed by 
employee prescription opioid use.     
There are many potential mechanisms for addressing the problems posed by 
                                                          
17  Andrea M. Garcia, State Laws Regulating Prescribing of Controlled Substances: Balancing the Pub-
lic Health Problems of Chronic Pain and Prescription Painkiller Abuse and Overdose, 41 J.L. MED. & ETH-
ICS 42, 42 (2013) (explaining that chronic pain affects 116 million adults in the United States). 
18  See Humphreys, supra note 12.  
19  Deborah A.P. Hersman, How the Prescription Drug Crisis is Impacting American Employers, NAT’L 
SAFETY COUNCIL (2017), https://www.nsc.org/Portals/0/Documents/NewsDocuments/2017/Media-Briefing-
National-Employer-Drug-Survey-Results.pdf.   
20  Genevieve Douglas, Opioid Addiction at Work Major Challenge for Employers, BLOOMBERG BNA 
(Mar. 14, 2017), https://www.bna.com/opioid-addiction-work-n57982085155/. 
21  Id. (paraphrasing Dr. Todd Simo, Chief Medical Officer for HireRight, an employment background 
check firm). 
22  Drugs at Work: What Employers Need to Know, NAT’L SAFETY COUNCIL (2017), 
https://www.nsc.org/work-safety/safety-topics/drugs-at-work. 
23  Katie Zezima & Abby Goodnough, Drug Testing Poses Quandary for Employers, N.Y. TIMES (Oct. 
24, 2010), http://www.nytimes.com/2010/10/25/us/25drugs.html (quoting Mark de Bernardo, senior partner at 
Jackson Lewis, an employment law firm) (emphasis added).  
24  See, e.g., Stacy Hickox, It’s Time to Rein in Employer Drug Testing, 11 HARV. L. & POL’Y REV. 419 
(2017) (discussing issues with workplace drug testing related to medical marijuana legalization); see also 
John B. Wefing, Employer Drug Testing: Disparate Judicial and Legislative Responses, 63 ALB. L. REV. 799, 
814–32 (2000) (providing a detailed inquiry into legal issues surrounding private employer drug testing). 
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drugs in the workplace, generally,25 and with respect to prescription opioids, specif-
ically.26  This Note will discuss just one such mechanism: mandatory state drug test-
ing guidelines.  The reason for this focus is twofold.   
First, mandatory state drug testing guidelines have the potential to clarify the 
expectations of both employers and employees, thereby protecting the interests of 
both.  From a public policy standpoint, it is important to address the conflict between 
employers and employees ex ante to avoid socially burdensome litigation down the 
road, which will necessarily compound the horrific impact that the prescription opi-
oid epidemic has already had on this country.   
Second, state law largely constitutes the legal landscape for restrictions on pri-
vate sector workplace drug testing, providing the fewif anylimitations on em-
ployment-at-will that exist in this context.  Thus, from a legal realism perspective, 
state law is the inevitable jumping-off point for policymakers going forward as they 
endeavor to strike the best balance between the interests of employers and employees 
related to employee prescription opioid use.  
Part I of this Note will further develop the debate surrounding workplace drug 
testing, focusing solely on the private sector.  This focus clearly encapsulates the 
dichotomy between employment-at-will and employee autonomy, without foraying 
into the constitutional issues that influence the same discussion in the public sector.  
Furthermore, in focusing exclusively on the private sector, this Note seeks to limit 
the discussion to state law mechanisms for regulating workplace drug testing, without 
delving into the further complexities added by federal regulation. 
Part II of this Note will then discuss how the issues surrounding workplace drug 
testing in the private sector are uniquely manifested by employee prescription opioid 
use, as compared to problem drugs of the past.   
Finally, Part III will explore the state law legal framework for workplace drug 
testing, focusing on how mandatory drug testing guidelines can help resolve policy 
concerns and thereby address just one piece of the massive social problem that is the 
prescription opioid epidemic. 
No existing state drug testing law is perfect as written, and the state law mecha-
nism is limited by design in terms of the goals it can achieve; to begin with, state 
drug testing laws have limited reach in the public sector, for example.  Notwithstand-
ing, this Note concludes that state law has the potential to play an important role in 
striking the balance between the policy objectives of employers and employees: a 
balance made all the more sensitive by the unique problems raised by prescription 
opioids.  On the one hand, many states are already on the right track in terms of laws 
that address these problems. State policymakers can learn from each another going 
forward as to how to better improve the balance between competing employer and 
employee objectives.  On the other hand, states that have thus far failed to address 
the issue of workplace drug testing with respect to prescription opioids are advised 
                                                          
25  See, e.g., Anne M. Rector, Use and Abuse of Urinalysis Testing in the Workplace: A Proposal for 
Federal Legislation Limiting Drug Screening, 35 EMORY L.J. 1011 (1986) (proposing standards for national 
legislation on workplace urinalysis testing). 
26  See, e.g., NAT’L SAFETY COUNCIL, THE PROACTIVE ROLE EMPLOYERS CAN TAKE: OPIOIDS IN THE 
WORKPLACE, (2018) available at, https://www.nsc.org/Portals/0/Documents/RxDrugOverdoseDocu-
ments/RxKit/The-Proactive-Role-Employers-Can-Take-Opioids-in-the-Workplace.pdf. 
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to note the approaches adopted by other states through positive legislation ex ante, 
rather than leaving it to the courts to resolve these policy issues ex post.  
 
I. AN OVERVIEW OF ISSUES SURROUNDING PRIVATE SECTOR WORKPLACE 
DRUG TESTING 
 
This Part will discuss how and why employers drug test their employees, and the 
means through which employees may challenge their employers’ prerogatives to do 
so.  As one author explains it, “[t]he question is not whether drug use, off-duty or on-
duty[,] is incompatible with employment.  Rather, the question is by what means it is 
permissible to come by evidence of such drug use.”27  In a private sector economy 
based on the doctrine of employment-at-will, employers historically have had “great 
autonomy” in developing policies to control the workplace and disciplining employ-
ees who fail to comply.28  This includes authority to develop workplace drug policies 
and testing programs to assess compliance with those policies; thus, “the decisions 
of who and when to test are mostly unfettered” for private sector employers. 29  His-
torically, drug testing became popular as testing accuracy increased and the cost of 
testing decreased.30  The trend toward testing was also “hastened” by the federal gov-
ernment’s promotion of “drug-free workplaces.”31   
While the law in this area generally favors employers, it is nonetheless difficult 
from a public policy perspective to determine where an employer’s right to control 
the work environment should end and where an employee’s right to do as she wishes 
on her own time should begin.32  On the one hand, from an employer’s perspective, 
drug use by employees contributes to a loss of workplace productivity, absenteeism, 
increased safety risks, and increased healthcare costs and workers’ compensation 
pay-outs.33  When employees are intoxicated at work, “damage to equipment and 
products, poor job performance, employer liability to other workers, employee theft, 
and the possession, buying, and selling of drugs in the workplace” may result.34  On 
the other hand, from an employee’s perspective, the implementation of workplace 
drug policies and the use of drug testing as a mechanism for enforcing those policies 
                                                          
27  Victor H. Smith, To Test or Not to Test: Is that the Question? Urinalysis Substance Screening of At 
Will Employees, 14 WM. MITCHELL L. REV. 393, 394 (1988).  
28  Wefing, supra note 24, at 815.  
29  Steven O’Neal Todd, Employee Drug TestingIssues facing Private Sector Employers, 65 N.C. L. 
REV. 832, 836 (1987). 
30  Id.; see also Tyler D. Hartwell, Paul D. Steele, Michael T. French, & Nathanial F. Rodman, Preva-
lence of Drug Testing in the Workplace, MONTHLY LAB. REV., Nov. 1996, at 35, available at 
https://www.bls.gov/mlr/1996/11/art4full.pdf (explaining that there was a “growing trend in the implementa-
tion of drug testing programs” amongst employers between the mid-1980s and mid-1990s).  
31  Wefing, supra note 24, at 816; see also Drug-Free Workplace Advisor, U.S. DEP’T OF LAB. (last vis-
ited Jan. 31, 2018), https://webapps.dol.gov/elaws/asp/drugfree/require.htm.  
32  Some states have adopted an aggressive approach to protecting employees on their own time, when 
they are not on their employers’ premises, such as New York, California, and Colorado.  These states prohibit 
discrimination by employers based on the legal off-duty conduct of their employees.  See, e.g., N.Y. LAB. 
LAW § 201-d (McKinney 1992); CAL. LAB. CODE § 96(k) (West 1999); COLO. REV. STAT. § 24-34-402.5 
(West 2007). 
33  Stephen M. Fogel, Gerri L. Kornblut, & Newton P. Porter, Survey of the Law on Employee Drug 
Testing, 42 U. MIAMI L. REV. 553, 559 (1988). 
34  Rector, supra note 25, at 1011.  
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raises privacy and confidentiality concerns. 35  Accuracy is also a concern when drug 
tests serve as the basis for adverse employment actions.36   
The tension between employer and employee interests related to workplace drug 
testing is exacerbated by issues surrounding the testing process.  In today’s work-
place, urine and hair tests are the most common methods of drug testing, with urinal-
ysis being the more common of the two methods.37  Commonly, workplace drug tests 
are conducted in two stages using a split sample.  The first is a screening test, often 
conducted on-site using an immunoassay or “low-cost chromatography.” The second 
is some form of “advanced chromatography,” often conducted at a laboratory con-
tracted by the employer.38   
Different drug testing techniques have different relative reliabilities, such that 
the appropriateness of using a particular test as the basis for an adverse employment 
action may vary.  For instance, thin layer chromatography (“TLC”) is “50 to 100 
times” less likely than an enzyme immunoassay (“EIA”) or radioimmunoassay 
(“RIA”) “to detect the presence of a drug,” and “1000 times” less sensitive than gas 
chromatography mass spectroscopy (“GC/MS”).39  Even when GC/MSthe most 
sensitive techniqueis used, the reliability of any conclusions drawn “depend[s] on 
such factors as the certainty of specimen identification; specimen storage, handling, 
and preparation; preparation and storage of test reagents; proper cleaning and cali-
bration of testing instruments and hardware; and the qualification and training of la-
boratory personnel.”40   
 Furthermore, even when reliable drug testing processes are used, a positive test 
result does not necessarily “indicate impairment” on the job.41  Rather, a positive test 
result establishes “some prior use” of a particular substance by the employee,42 as 
evidenced by the presence of a metabolite of that substance in the employee’s system.  
Obviously, employers’ concerns with employee drug use depend to some degree on 
the circumstances under which that drug use occurs; drug use on the job presents 
different problems from off-duty use, and off-duty use may present different prob-
lems from off-duty drug abuse.  To the extent that a positive drug test cannot distin-
guish these different behaviors, an important policy question is raised as to “whether 
a positive drug test, without other evidence of negative effects of drug usage, should 
be the basis for important employment decisions” at all.43   
                                                          
35  Hickox, supra note 24, at 421 (explaining that “forcing” employees to “provide a urine or hair speci-
men” raises privacy concerns for employees).   
36  See id. at 425 (explaining that “[b]ecause drug testing does not measure impairment and frequently 
provides false positive test results, it fails to fulfill the interests for which employers rely on it.”).  
37  Wefing, supra note 24, at 827–28. 
38  Scott S. Cairns & Carolyn V. Grady, Drug Testing in the Workplace: A Reasoned Approach for Pri-
vate Employers, 12 GEO. MASON L. REV. 491, 501 (1990).  
39  1 WILLIAM E. HARTSFIELD, INVESTIGATING EMPLOYEE CONDUCT § 3:75 (2018).  
40  2 KEVIN B. ZEESE, DRUG TESTING LEGAL MANUAL, § 6:48 (2nd ed. 2018)(quoting Nat’l Treasury 
Emp. Union v. Von Raab, 649 F.Supp. 380 (E.D. La. 1986)).).  
41  Hickox, supra note 24 at 426. 
42  Id.  Testing for the presence of drug metabolites in an employee’s system should be distinguished 
from testing for alcohol consumption; a breathalyzer test would indeed measure employee impairment from 
alcohol consumption. 
43  Id. at 420.  
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At-will employees may pose legal challenges to drug testing on the common law 
grounds tort and contract,44 under state constitutional protections of privacy and state 
laws prohibiting handicap discrimination.45  Private sector employees do not have a 
cause of action under the federal constitutional protections of the right to privacy, the 
right to be free from unreasonable searches and seizures, or the right to due process46: 
the fronts on which much public sector employee drug testing litigation has histori-
cally occurred.  Private sector employees are afforded some protection at the federal 
level under the Americans with Disabilities Act (ADA) if they are able to demonstrate 
a disability within the meaning of the Act.47  Alternatively, employees may have a 
cause of action under state law.  State law approaches will be discussed in further 
detail in Part III, infra.   
In sum, drug testing in the workplace creates tension between the interests of 
employers and their employees; this tension produces a minefield of potential 
grounds for litigation.  This Note predicts that, as the effects of the prescription opioid 
epidemic are realized over time, courts will increasingly be tasked with resolving 
sticky controversies related to prescription opioid use in the workplace and will strug-
gle to find the right balance between the competing interests of employers and em-
ployees in this context.  Conversely, as this Note advocates, this tension can be re-
solved in some measure ex ante by state workplace drug testing laws, as discussed in 
Part III, infra.  
 
II.  THE PRESCRIPTION OPIOID EPIDEMIC MEETS THE AMERICAN WORKPLACE 
 
This Part will explain the unique issues raised by drug testing for prescription 
opioids, considering these drugs’ legal status, medicinal application, potency, and 
prevalence.  At the present time, drug testing for prescription opioids is not prevalent; 
National Public Radio reports that only thirteen percent of drug screens used test for 
prescription opioids, according to data collected by Quest Diagnostics, a drug testing 
firm.48  There is a strong incentive, however, for employers to develop effective 
workplace policies on prescription opioids based on the potential costs of unclear 
                                                          
44  Steven O’Neal Todd, Note, Employee Drug Testing—Issues Facing Private Sector Employers, 
65 N.C. L. REV. 832, 835 (1987). 
45  § 20:163: Overview of State Laws Regulating Substance Abuse Testing, EMP. DISCRIM. COORD., 
NOV. 2018 [hereinafter Overview]. 
46  See Todd, supra note 44, at 833.    
47  The ADA specifies that current use of an illegal drug does not qualify as a disability under the Act.  
On the other hand, the ADA “does not exclude individuals who have successfully completed a drug rehabilita-
tion program” or “individuals erroneously regarded as engaging in the illegal use of drugs.”  Margaret C. Jas-
per, Medical Examinations – Drug and Alcohol Addiction, LEGAL ALMANAC: THE AMERICANS WITH DISA-
BILITIES ACT § 2:20 (2012).  See also Shirley v. Precision Castparts Corp., 726 F.3d 675 (5th Cir. 2013) 
(holding that an employee’s illegal use of prescription painkillers did not qualify for protection under the 
ADA).  On the other hand, an employee with a qualifying disability who takes prescription painkillers as a 
function of that disability may be protected under the ADA.  But see Elisa Y. Lee., Note, An American Way of 
Life: Prescription Drug Use in the Modern ADA Workplace, 45 COLUM. J.L. & SOC. PROBS. 303, 305 (2011) 
(citing Bates v. Dura Automotive Sys., 625 F.3d 283 (6th Cir. 2010) (reversing the District Court’s denial of 
summary judgment to the employer regarding the termination of several employees for prescription opioid use 
because the employees in question were not disabled so as to qualify for protection under the ADA in the first 
instance)).   
48  Noguchi, supra note 11.  
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expectations and ensuing conflict.49  This Note predicts that drug testing for prescrip-
tion opioids will become increasingly popular in the future.    
This trend will raise the same concerns as testing for any drug, as discussed in 
Part I, supra.  Developing a workplace prescription opioid policy may be tricky for 
employers; in light of accuracy issues and the risk of false positives, opioid testing 
may “[fail] to fulfill the interests for which employers rely on it.”50  Because drug 
tests do not actually measure on-the-job impairment, employers may be unable to 
distinguish via drug tests between employees who have lingering traces of medicine 
in their systems and employees who are “high on Percodan.”51   
Drug testing for prescription opioids also raises problems that are not relevant to 
testing for other substances of abuse, making the issue even more complex.  For one 
thing, the legal status of prescription opioids at both the state and federal level simply 
cannot be ignored, and certainly serves to distinguish prescription opioids from the 
“national scourge[s]” of the past as well as hot-button issues of the modern day, like 
medical marijuana.52  The main goal of most existing drug screens is “to deter em-
ployee use of illicit substances, not legal ones.”53  Prescription opioids play an im-
portant role in pain control in modern American medicine, unlike other substances of 
abuse: a fact that is all too easily forgotten in the panic of discussing the epidemic.  
As Dr. Nora Volkow explained in a presentation to the Senate Caucus on Interna-
tional Narcotics Control, prescription opioids present a “complex problem” and de-
mand that a balance be struck between “providing maximum relief from suffering 
while minimizing associated risks and adverse effects.”54    
Unlike other substances of abuse, employers may not necessarily benefit from a 
hardline stance against employee prescription opioid use.  In some cases, an em-
ployee may use prescription opioids to counteract pain caused by her “vocation’s 
physical demands.”55  Taking into account factors such as timing and dosage, “many 
users [can] function normally” despite the “serious risks” posed by these powerful 
drugs.56  Thus, employers may actually benefit from the productivity of a workforce 
that has found effective ways to combat pain on the job; there is cruel irony in pre-
venting employees from taking painkillers when the source of the pain is their em-
ployment.  Still, common side effects from prescription opioid use can include drows-
iness, reduced coordination, blurred vision, anxiety, and depression.57  
Unsurprisingly, employers of employees in safety-sensitive occupations—such as 
jobs involving hazardous machinery or that implicate the public health in some way, 
including jobs in the transportation industry—will find this disconcerting; they may 
not be placated by the fact that some employees will not suffer adverse side effects 
                                                          
49  See Douglas, supra note 20. 
50  Hickox, supra note 24, at 424. 
51  Noguchi, supra note 11.  
52  See generally Hickox, supra note 24 (discussing issues surrounding workplace drug policies on med-
ical marijuana). 
53  Douglas, supra note 20 (paraphrasing Dr. Todd Simo).  
54  Volkow, supra note 13.  
55  Robert E. Ammons, A Silent Epidemic, AM. ASS’N FOR JUST, 23-FEB TRIAL 22, 23 (2017) (explain-
ing that truck drivers often manage chronic pain associated with their occupation with prescription opioids). 
56  Zezima & Goodnough, supra note 23. 
57  Ammons, supra note 55, at 23. 
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on the job.58   
Furthermore, it may be difficult and costly for employers to police the line be-
tween stable, legitimate prescription opioid use and misuse or abuse.  Because pre-
scription opioids are so powerful, even an employee who obtained prescription opi-
oids pursuant to a doctor’s prescription can fall on a “path to dependency.”59  An 
employee who abuses opioids “may struggle to maintain regular attendance, achieve 
quality goals, or pose a safety hazard to him or herself and coworkers.”60  A publica-
tion for the American Association of Justice by attorney Robert Ammons illustrates 
the issue: Ammons suggested that opioid use among long-distance truck drivers in-
creasingly leads to accidents on the road, a phenomenon he dubbed the “silent epi-
demic” in light of the fact that “some truck drivers, motor carriers, and even physi-
cians fail to fully appreciate the risks associated with opioid use.”61   
Finally, employers may also need to be concerned about the social consequences 
of the policies they choose to implement.  Cutting loose employees with suspected 
substance abuse problems may be socially problematic insofar as it denies those em-
ployees financial and social support during a time of personal crisis.  Unemployment 
can also deepen opioid-related depression and even lead to “more drastic outcomes 
… including intentional or accidental overdose.”62  Additionally, employers should 
also be aware that employees may in some cases obtain prescription opioids through 
employer-provided health insurance, adding a layer of moral accountability to the 
equation, even in the absence of legal accountability.  The NSC has advanced the 
story of a machinist named Bill Butler as a precautionary tale.  Butler was prescribed 
hydrocodone for occupation-induced lower back pain.63  “After developing a toler-
ance,” Butler began taking methadone, one of the most potent and dangerous pre-
scription painkillers.64  Butler was injured at work, but overdosed at home at thirty-
three years old.65    
All of these issues merit careful consideration.  The ball effectively remains in 
the employers’ courts under the prevailing doctrine of employment-at-will to estab-
lish workplace drug policies that meet their needs.  To the extent that the opioid crisis 
                                                          
58  See Todd, supra note 44, at 833. 
59  Edwin Foulke, Jr. & Travis Vance, America’s Opioid Epidemic and the Workplace: Should Employ-
ers Change Their Approach to Drug Testing?, WORKPLACE SAFETY & HEALTH L. BLOG (July 31, 2017), 
https://www.fisherphillips.com/Workplace-Safety-and-Health-Law-Blog/americas-opioid-epidemic-and-the-
workplace-should. 
60  Id.  
61  Ammons, supra note 55, at 23.  On October 1, 2017, new federal mandatory guidelines for work-
place drug testing became effective, including Department of Transportation authority to test for oxycodone 
and hydrocodone, among other “semi-synthetic opioids.”  See Mandatory Guidelines for Urine Testing Up-
dated to Include Four Semi-Synthetic Opioids, S.A.M.H.S.A. (Sept. 29, 2017), https://www.sam-
hsa.gov/newsroom/press-announcements/201709291000. 
62  Foulke & Vance, supra note 59.  
63  Sarah Trotto, Prescription Painkillers and the Workforce: Experts Say Policies and Education Can 
Help Combat Opioid Abuse, NAT’L SAFETY COUNCIL (Sept. 27, 2015), http://www.safetyandhealthmaga-
zine.com/articles/12932-prescription-drugs-workers. 
64  Id.; see also Maia Szalavitz, Methadone: A Major Driver of Prescription Painkiller Overdose 
Deaths, TIME MAG. (July 3, 2012), http://healthland.time.com/2012/07/03/methadone-a-major-driver-of-pre-
scription-painkiller-overdose-deaths/. 
65  Drugs at Work: What Employers Need to Know, NAT’L SAFETY COUNCIL (2017), 
http://www.nsc.org/learn/NSC-Initiatives/Pages/prescription-painkillers-for-employers.aspx. 
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is not on their “radar screens as much as it should be,”66 employers may need to 
“rethink” their drug testing policies “in order to keep their employees and work-
place[s] safe.”67  The NSC recommends that employers take a “proactive role” in 
combatting the prescription opioid epidemic by “reevaluating” workplace drug poli-
cies and working with healthcare plan providers to “understand the extent of opioid 
use and the need for programs to prevent and manage opioid abuse.”68   
   
III. THE ROLE OF STATE LAW IN ADDRESSING THE PRESCRIPTION OPIOID 
PROBLEM  
 
This Part will discuss state law approaches to workplace drug testing, first by 
broadly classifying these different approaches and then by explaining why the imple-
mentation of mandatory state drug testing guidelines—through positive legislation—
is the best approach.  Then, this Part will analyze the drug testing laws of the thirteen 
states with mandatory state drug testing guidelines currently enacted, highlighting 
specific protections that appear in these various laws that can help strike the balance 
between employer and employee interests related to employee prescription opioid 
use, to the benefit of all.   
This discussion is premised on the notion that it is unreasonable to expect that 
employers can or will address the myriad public policy concerns discussed in Part II, 
supra on their own without legislative guidance; rather, they can be expected to act 
in their own interests, to minimize their own costs.  Because there are so many issues 
surrounding drug testing for prescription opioids and the consequences of bad policy 
are so severe, the rule of law is needed to referee the interests of employers and em-
ployees: to protect employees while remaining sensitive to the needs of employers.  
Because state law provides the few, if any, limitations on employment-at-will that 
exist, it is the best starting point for discussing how this balance should be struck.   
The state law legal landscape on workplace drug testing may be best described 
as a “patchwork”,69 as states have adopted myriad approaches to regulating drug test-
ing in the workplace.  For example, some states have adopted statutes that specify 
drug testing policy and procedure with varying degrees of detail, while a substantial 
number of states have “left it to the judiciary” entirely to develop “common law 
rules” on the subject.70  In general it may be noted, however, that  “[state] courts have 
imposed very few constraints on drug testing by private sector employers.”71  Thus, 
by and large, restrictions on workplace drug testing have come from state legislatures, 
rather than the courts.   
There is significant variation in the substantive content of these laws across the 
                                                          
66  Zezima & Goodnough, supra note 23 (quoting Mark de Bernardo, senior partner at Jackson Lewis, an 
employment law firm).  
67  Foulke & Vance, supra note 59.    
68  See The Proactive Role Employers Can Take: Opioids in the Workplace, supra note 26. 
69  Hickox, supra note 24, at 420.  
70  Wefing, supra note 24, at 816.  
71  Hickox, supra note 24, at 420.    
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spectrum, as well.  Thirteen states have mandatory drug testing guidelines72 that im-
pose legislatively-defined parameters on employers if they are to drug test their em-
ployees at all.73  Such mandatory rules may be comprehensive in nature or merely 
procedural.74  Procedural laws typically “establish procedural requirements govern-
ing specimen collection, labeling, and chain-of-custody; testing lab certification; 
screening and confirmed test requirements; and in some cases, specific cut-offs for 
positive drug testing levels.”75  Comprehensive laws, on the other hand, “limit the 
circumstances under which an employer can test and regulate all aspects of testing,” 
thereby governing both substance and procedure.76    
Of the thirty-seven states without mandatory drug testing guidelines, some pro-
vide premium discounts for workers’ compensation insurance for employers who 
participate in voluntary drug-free workplace programs (DFWP).77  There are eleven 
states with such programs.78 Other states have “[s]tatutory incentives” for employers 
to implement drug policies, such as “a defense to a worker’s compensation claim and 
a defense to an unemployment compensation claim.”79  Three states fall into this 
category.80  Finally, twenty-three states have no general statute covering workplace 
drug testing.81  These states restrict private sector workplace drug testing through the 
common law, if at all, or completely “defer” to employment-at-will.82 
 
                                                          
72  See Workplace Drug Testing State Laws, NAT’L DRUG SCREENING, INC. (2018), https://www.natio-
naldrugscreening.com/; see also CONN. GEN. STAT. ANN. § 31-51u (West 1995); HAW. REV. STAT. ANN. § 
329B-1 (West 1990); IOWA CODE ANN. 730.5 (West 2017); LA. STAT. ANN. § 49:1002 (2015); ME. REV. 
STAT. ANN. tit. 26, § 681 (2011); MD. CODE ANN., HEALTH-GEN § 17-214 (West 2017); MINN. STAT. ANN. § 
152.02 (West 2017); MONT. CODE ANN. § 39-2-206 (West 2011); NEB. REV. STAT. ANN. § 48-1902 (West 
2010); OKLA. STAT. ANN. TIT. 40, § 551 (West 2011); R.I. GEN. LAWS ANN. § 28-6.5-1 (West 2013); UTAH 
CODE ANN. § 34-38-1 (West 2010); VT. STAT. ANN. TIT. 21, § 511 (West 2001).  
73  See, e.g., ME. REV. STAT. ANN. TIT. 26, § 681(2) (2011) (“[t]his subchapter does not require or en-
courage employers to conduct substance abuse testing of employees or applicants. An employer who chooses 
to conduct such testing is limited by this subchapter, but may establish policies which are supplemental to and 
not inconsistent with this subchapter.”).  
74  See Overview, supra note 45 (explaining that Connecticut, Iowa, Maine, Minnesota, Utah, and Ver-
mont have comprehensive drug testing laws, while Hawaii, Louisiana, Maryland, Nebraska, Oklahoma, and 
Rhode Island have only procedural drug testing laws).   
75  Id.   
76  Id.  
77  See id.  
78  ALA. CODE. § 25-5-332 (West 1995); ARK. CODE ANN. § 11-14-112 (West 1999); ARK. ADMIN. 
CODE 099.00.1-099.36 (LexisNexis 2008); FLA. STAT. ANN. § 440.102(2) (West 2017); GA. CODE ANN. § 34-
9-412 (West 2001); IDAHO CODE ANN. § 72-1716 (West 2003); KY. REV. STAT. ANN. § 304.13-167 (West 
2000); N.Y. COMP. CODES R. & REGS. TIT. 12, § 60 (West 2009); OHIO REV. CODE ANN. § 4123.54 (West 
2017); S.C. CODE ANN. § 44-107-10 (1990); TENN. CODE ANN. § 50-9-101 (West 2016); 2 WYO. CODE R. § 9 
(LexisNexis 2017). 
79  Patricia A. Montgomery, Workplace Drug Testing: Are There Limits?, 32-APR TENN. B.J. 20, 21 
(1996). 
80  See Overview, supra note 45. See ALSO ALASKA STAT. § 23.10.615 (West 1997); MISS. CODE ANN. § 
71-7-3 (West 2004); ARIZ. REV. STAT. ANN. § 23-493.06 (West 1994).  
81  See Overview, supra note 45. These states include California, Colorado, Delaware, Indiana, Illinois, 
Kansas, Massachusetts, Michigan, Missouri, New Hampshire, New Jersey, New Mexico, North Carolina, 
North Dakota, Nevada, Oregon, Pennsylvania, South Dakota, Texas, Virginia, Washington, West Virginia, 
and Wisconsin.  
82  Hickox, supra note 24, at 420. 
  
136 Journal of Legislation [Vol. 45:6] 






incentives85 No general statute
86 
Connecticut Alabama Alaska California North Caro-lina 
Hawaii Arkansas Arizona Colorado North Dakota 
Iowa Florida Mississippi Delaware Nevada 
Louisiana Georgia  Indiana Oregon 
Maine Idaho  Illinois Pennsylvania 
Maryland Kentucky  Kansas South Dakota 
Minnesota New York  Massachusetts Texas 
Montana Ohio  Michigan Virginia 
Nebraska South Carolina  Missouri Washington 
Oklahoma Tennessee  New Hamp-shire West Virginia 
Rhode Island Wyoming  New Jersey Wisconsin 
Utah   New Mexico  
Vermont     
 
An examination of this “patchwork” reveals glaring gaps in employee protec-
tion.87  Only eight percent of the American workforce is protected by mandatory drug 
testing laws,88 and no state has a law that “protect[s] the employment of one who 
tests positive on a drug test but shows no sign of impairment at work.”89  Even states 
with mandatory drug testing guidelines “generally fail to provide … employees with 
any private cause of action through which they can challenge an employer's employ-
ment decision based on a drug test that does not adhere to these standards.”90  Essen-
tially, this means that the state laws currently enacted that cover the vast majority of 
American employees do not really strike the balance between employer and em-
ployee interests at all; rather, they inevitably favor the employer.  
Notwithstanding these trends, a few states have robust workplace drug testing 
laws that afford substantial protection to employee interests.  Given that there is gen-
eral inertia in the courts to abrogate employer autonomy related to workplace drug 
testing, positive legislation is necessary to promote uniformity and consistency in the 
law.  Mandatory state drug testing guidelines inherently strike a more sensitive bal-
ance between the interests of employers and employees than any form of voluntary 
or opt-in law, given the default to employer discretion under the prevailing doctrine 
of employment-at-will.   
In an analysis of the thirteen states with mandatory drug testing guidelines, cer-
tain patterns emerge.  In particular, certain types of provisions appear in many of 
                                                          
83  See supra note 72 (listing state statutes that impose mandatory drug testing guidelines).  
84  See supra note 78 (listing state statutes that include voluntary drug-free workplace programs).    
85  See supra note 80 (listing state statutes with statutory incentives for employers to adopt workplace 
drug policies). 
86  See supra note 81 (listing states without a general statute covering workplace drug testing).  
87  Hickox, supra note 24, at 420. 
88  Id. at 435–36.  
89  Id. at 433.   
90  Id.   
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these state laws, which may serve the interests of employers and employees alike, 
while also promoting broader social goals in this context.  These key provisions are 
summarized below and include: A) the opportunity for an employee to provide infor-
mation when an employee tests positive; B) confirmatory drug testing before an ad-
verse employment action is taken; C) medical review officer (“MRO”) review of em-
ployee drug test results; D) limiting drug testing to circumstances of “reasonable 
suspicion”; E) mandatory employee assistance program (“EAP”) counseling before 
an employee can be terminated; and F) a private right of action for employer non-
compliance with the law. 
 
A. The Opportunity to Provide Information when an Employee Tests Positive 
 
The purpose of a legislatively-mandated opportunity to provide information is to 
allow an employee the opportunity to justify a positive drug test result with evidence 
of prescribed use, so as to allay her employer’s concerns that such drug use is actually 
detrimental to her job.  There are eight states with mandatory drug testing guidelines, 
which require employers to provide their employees an opportunity to identify legit-
imate prescription drug use or to rebut a positive drug test with information to that 
effect, before an adverse employment action may be taken against them.91  For ex-
ample, Iowa’s drug testing law provides: 
An employee or prospective employee shall be provided an opportunity to 
provide any information which may be considered relevant to the test, in-
cluding identification of prescription or nonprescription drugs currently or 
recently used, or other relevant medical information. To assist an em-
ployee or prospective employee in providing the information described in 
this subparagraph, the employer shall provide an employee or prospective 
employee with a list of the drugs to be tested.92 
There are different metabolites for different types of opioids that may appear on 
a positive drug test; for example, the primary metabolite of heroin is different from 
hydrocodone.93  Thus, drug tests may be able to distinguish between illicit and non-
illicit substances, to some degree.  The opportunity to provide information is im-
portant, however, because drug tests cannot distinguish between illicit and non-illicit 
use.  This means that from an employer’s perspective, two positive drug tests—one 
from an employee taking prescription opioids pursuant to a doctor’s prescription and 
one from an employee who illegally obtained and is abusing prescription opioids—
are indistinguishable.  The potential for unfairness is manifest when adverse employ-
ment actions are taken solely based on such information. 
                                                          
91  Id. at 439.  These states are Iowa, Louisiana, Maine, Maryland, Minnesota, Montana, Rhode Island 
and Utah.  
92  IOWA CODE ANN. § 730.5(c)(2) (West 2017). 
93  Opiates, MAYO CLINIC (2018) https://www.mayomedicallaboratories.com/test-info/drug-book/opi-
ates.html (explaining that the presence of 6-MAM, a primary metabolite of heroin, is “conclusive evidence of 
prior heroin use” and explaining further that the primary metabolites of hydrocodone are hydromorphone and 
norhydrocodone).  
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Both employers and employees stand to benefit from fostering a workplace en-
vironment “conducive to the free exchange of information.”94  In general, “[a]n op-
portunity to contest test results with other information showing a lack of impairment 
at work is important to protect the interests of . . . employees,”95 but employers will 
also be better able to make informed decisions about their employees’ conduct when 
they are armed with all of the facts.    
This peachy picture of cooperation is eroded somewhat by the fact that very few 
states actually “control an employer’s response to a positive drug test.”96  In Louisi-
ana, which imposes the Substance Abuse and Mental Health Administration’s 
(“SAMHSA”) federal drug testing guidelines on private sector employers, an MRO 
must contact the drug tested employee to determine if there is a legitimate medical 
explanation for a positive test result.97  If a legitimate explanation exists—“e.g., a 
valid prescription”—the medical review officer “reports the test result as negative.”98  
Similarly, Montana prohibits “adverse action” from being taken based on a positive 
drug test “if the employee presents a reasonable explanation or medical opinion in-
dicating that the original test results were not caused by illegal use of controlled sub-
stances.”99  
In other states, the ball is still in the employer’s court to act favorably or unfa-
vorably upon the information that an employee tested positive, even for a valid med-
ical reason.  On the one hand, this approach respects employer discretion; on the 
other, it undermines employee privacy.  It would be socially beneficial in the context 
of the prescription opioid epidemic for state law to model the approaches of Louisi-
ana and Montana, such that a positive drug test is automatically excused when there 
is a legitimate medical explanation.  This will prevent employers from unnecessarily 
interfering with their employees’ medical concerns and will additionally promote a 
relationship of trust between employer and employee.   
 
B. Confirmatory Drug Testing before an Adverse Employment Action is 
Taken 
 
Confirmatory drug testing alleviates some of the accuracy issues with drug test-
ing and encourages employers to have substantiated evidence of drug use before dis-
ciplining their employees.  Such a policy is the exception, not the norm, however; “in 
the overwhelming majority of states, a single hair or urinalysis can result in an ad-
verse employment decision.”100   
Contrastingly, seventeen states require a “confirmatory test of an initial positive 
                                                          
94  How Employers Can Help Address America’s Opioid Epidemic, FISHER PHILLIPS (Sept. 5, 2017), 
https://www.fisherphillips.com/resources-newsletters-article-how-employers-can-help-address-americas-opi-
oid-epidemic. 
95  Hickox, supra note 24, at 458–59.  
96  Id. at 439.   
97  Mandatory Guidelines for Federal Workplace Drug Testing Programs, 80 Fed. Reg. 94, 28101 & 
28105 (May 15, 2015), https://www.gpo.gov/fdsys/pkg/FR-2015-05-15/pdf/2015-11524.pdf [hereinafter Man-
datory Guidelines]. 
98  Id. 
99  MONT. CODE ANN. § 39-2-210 (West 2011). 
100  Hickox, supra note 24, at 437.  
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test result” before employers can take adverse employment actions against their em-
ployees.101  Of the thirteen states with mandatory drug testing guidelines discussed 
above, twelve explicitly require a confirmatory drug test after an initial on-site posi-
tive screening exam, unless the tested employee fails to show up for the confirmatory 
test.102  In the latter case, the employer may generally consider the no-show a failed 
test.  For example, in Connecticut, the law states that no adverse employment action 
may be taken unless an initial urinalysis exam “utilizing a reliable methodology” 
yields a positive result and that result is confirmed by a “separate and independent” 
test using GC/MS or an equal or more reliable technique.103  Several states, including 
Connecticut, explicitly require the use of GC/MS or a comparably reliable technique 
for all confirmatory tests.104  Other state laws stipulate that confirmatory testing must 
be conducted at a laboratory meeting certain qualifications.105  For example, under 
Iowa law, “[a]ll confirmatory drug testing shall be conducted” at a SAMHSA-certi-
fied laboratory.106   
Both employers and employees stand to benefit from the imposition of a con-
firmatory testing rule.  From an employer’s perspective, “anything less than perfec-
tion” in the accuracy of testing procedures “affects the cost effectiveness of the pro-
gram.”107  Thus, confirmatory drug tests help reduce unnecessary employee turnover 
and protect employers’ investments in their employees.  According to one article, 
“[a] survey of twenty-five technical experts revealed that GC/MS is the only confir-
mation test that, when used in conjunction with [an immunoassay], is rated [as] fully 
defensible against legal challenge for a wide range of drugs.”108  Thus, employers 
may be able to better shield themselves from litigation by disgruntled former em-
ployees when a confirmatory test is mandated by law.   
The potential downside of using confirmatory GC/MS testing from an em-
ployer’s perspective is its relative cost.109  It is important to consider, however, that 
the “unavoidable result of employer reliance on inaccurate urinalysis tests” is the 
“discipline and discharge of some innocent employees,” which is simply a different 
type of cost to the employer.110   
                                                          
101  Id.  
102  These states are Connecticut, Hawaii, Iowa, Montana, Rhode Island, Nebraska, Oklahoma, Utah, 
Vermont, Maine, Maryland, and Minnesota.  
103  CONN. GEN. STAT. ANN. § 31-51u(a) (West 1995). 
104  These states are Hawaii, Iowa, Montana, Rhode Island, Nebraska, Oklahoma, Utah and Vermont. 
See CONN. GEN. STAT. ANN. § 31-51u(a) (West 1995); HAW. REV. STAT. ANN. § 329B-4(6) (West 1999); 
IOWA CODE ANN. § 730.5(f)(1) (West 2017); MONT. CODE ANN. § 39-2-207(4) (West 2005); R.I. GEN. LAWS 
ANN. § 28-6.5-1(a)(4) (West 2013); NEB. REV. STAT. ANN. § 48-1903(1) (West 2000); OKLA. STAT. ANN. tit. 
40, § 559(8) (West 1993); UTAH CODE ANN. § 34-38-6(6)(b) (West 2010); VT. STAT. ANN. tit. 21, § 
514(6)(A) (West 2001). 
105  See IOWA CODE ANN. § 730.5(e) (West 2017); HAW. REV. STAT. ANN. § 329B-5.5(3) (West 2007); 
ME. REV. STAT. ANN. tit. 26, § 683(5-A)(B) (2011); MD. CODE ANN., HEALTH-GEN § 17-214(f)(1)(ii) (West 
2017); MINN. STAT. ANN. § 181.953(3) (West 2004); MONT. CODE ANN. § 39-2-207(4) (West 2005); R.I. 
GEN. LAWS ANN. § 28-6.5-1(a)(4) (West 2013); NEB. REV. STAT. ANN. § 48-1903 (West 2000); UTAH CODE 
ANN. § 34-38-6(6)(b) (West 2010); VT. STAT. ANN. tit. 21, § 514(6)(A) (West 2001). 
106  IOWA CODE ANN. § 730.5(e) (West 2017).  
107  Smith, supra note 27, at 407.  
108  Fogel, Kornblut, & Porter, supra note 33, at 555–56 (internal quotations omitted). 
109  Rector, supra note 25, at 1018.  
110  Id. at 1068.  
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From the perspective of the employee, a more sensitive GC/MS test, as compared 
with an immunoassay—particularly when the confirmatory test is conducted at a cer-
tified laboratory rather than on-site—reduces the risk of a false positive result,111 
thereby affording the employee greater job security and protection from unfair disci-
pline.  The use of a confirmatory test via the GC/MS technique also helps to address 
the fact that drug tests do not actually measure impairment.112  As one author explains 
it, neither an EIA nor a GC test in isolation can “accurately identify drug use—only 
the MS test can accurately identify drug ingestion.”113  Given the myriad procedural 
issues with workplace drug testing, employees can only benefit when more accurate 
testing techniques are mandated by law.  
While the foregoing conclusions about the importance of test accuracy may be 
drawn with respect to any substance to be tested, the stakes are higher in the prescrip-
tion opioid context for the public policy reasons discussed in Part II, supra.  Drug 
testing for prescription opioids already puts employees between a rock and a hard 
place, in terms of protecting their job security and having the freedom to take legally 
prescribed medication to address their health issues.  Irrespective of the employer’s 
prerogative to test, no party stands to gain when employees are disciplined based on 
false positive test results.  Thus, confirmatory drug testing should be required by state 
law.   
C. MRO Review of Employee Drug Test Results 
An MRO—medical review officer—is a neutral third party who helps to ensure 
the medical legitimacy of drug tests.  Like confirmatory drug testing, the use of an 
MRO is the exception rather than the norm.  While “[a]ll federal agency and federally 
regulated drug testing programs” require the use of a MRO to “review drug test re-
sults,”114 only ten states require the involvement of an MRO during the drug testing 
process.115  In some states, like Montana, the role of the MRO is clearly defined to 
include the authority to consider prescription drug use by the employee being tested:  
Before an employer may take any action based on a positive test result, the 
employer shall have the results reviewed and certified by a medical review 
officer who is trained in the field of substance abuse. An employee or pro-
spective employee must be given the opportunity to provide notification to 
the medical review officer of any medical information that is relevant to 
interpreting test results, including information concerning currently or re-
cently used prescription or nonprescription drugs.116 
                                                          
111  See Alan E. Denenburg, Corporate Drug Testing: Private Employers’ Right to Test, 12 DEL. J. 
CORP. L. 951, 981 (1987).  
112  See Hickox, supra note 24, at 426.  
113  Rector, supra note 25, at 1067.  
114  Medical Review Officers—In General, DRUG TESTING L., TECH. AND PRAC. § 4:73 (2017) [herein-
after Medical Review Officers]. 
115  Hickox, supra note 24, at 437.  Seven states with mandatory drug testing guidelines require the in-
volvement of an MRO, including Hawaii, Iowa, Louisiana, Maryland, Rhode Island, Oklahoma, and Vermont. 
Id.   
116  MONT. CODE ANN. § 39-2-207(5) (West 2005); see also IOWA CODE ANN. § 730.5(g) (West 2017); 
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In some cases, an MRO may actually report a test result as negative when a pos-
itive result is justified by a legitimate medical explanation.117 
As Hickox explains in her article, “[u]se of a . . . (MRO) is another important 
piece of the drug testing process to ensure the reliability of test results.”118  This is so 
because “[a] positive laboratory test result does not automatically identify an em-
ployee . . . as an illegal drug user.”119  The MRO, armed with “detailed knowledge 
of possible alternative medical explanations,” may be able to review an employee’s 
positive test result more sensitively than an employer otherwise would.120  Without 
an MRO, and especially when employees are not guaranteed an opportunity to ex-
plain positive test results, employers can simply respond “as they see fit”121 to a pos-
itive drug test, notwithstanding that discipline in certain circumstances may neither 
be fair or desirable.   
 Without MRO review, employees lose the benefit of expert medical review that 
can allow for some discretion in the drug testing procedures, which the tests them-
selves do not provide.  While a test cannot distinguish between prescription opioids 
obtained legitimately or illegitimately, an MRO can make that determination in favor 
of the employee and report a negative test result when he or she finds that a bona fide 
prescription has led to a positive test result.  From an employer’s perspective, the use 
of an MRO adds to the cost-benefit analysis of a drug testing program.  As Hickox 
explains, “[t]he absence of MRO review has been described as a source of legal lia-
bility and problems for companies and laboratories.”122  MRO involvement in the 
drug testing process is therefore essential, and should be guaranteed by state law, as 
a first line of defense for employers and employees alike.    
 
D. Limiting drug testing to Circumstances of “Reasonable Suspicion” 
 
At common law, employers have substantial leeway in deciding whom to drug 
test and when.  Most states allow random drug testing of employees, meaning that an 
employee can be subjected to a drug test—thereby putting his or her job on the line—
without cause.  Just four of the states with mandatory drug testing guidelines listed 
above require employers to have some level of suspicion of employee drug use in 
order to test employees in the ordinary course of work, including Connecticut, Min-
nesota, Rhode Island, and Vermont.123  A ‘suspicion’ requirement erodes some of 
the employer’s discretion and thereby provides greater protection to the employee.  
So long as the employee is not behaving ‘suspiciously’—however that is defined by 
                                                          
LA. STAT. ANN. § 49:1001(5) (2015); OKLA. STAT. ANN. tit. 40, § 552(11) (West 2012); VT. STAT. ANN. tit. 
21, § 514(9) (West 2001).  
117  Hickox, supra note 24, at 425; see also Mandatory Guidelines, supra note 97.  The Mandatory 
Guidelines are incorporated in Louisiana’s drug testing statute.  
118  Hickox, supra note 24, at 425; see also Mandatory Guidelines, supra note 97, at 28105. 
119  Medical Review Officers, supra note 114.  
120  Id. 
121  See Hickox, supra note 24, at 440.  
122  Id. at 425. (quoting Kim Broadwell, The Evolution of Workplace Drug Screening: A Medical Re-
view Officer's Perspective, 22 J.L. MED. & ETHICS, 240, 241 (1994) (internal quotations omitted)).   
123  See CONN. GEN. STAT. ANN. § 31-51x (2016); MINN. STAT. ANN. § 181.951 subd. 4(1)-(4) (2005); 
28 R.I. GEN. LAWS ANN. § 28-6.5-1(a)(1) (West 2013); VT. STAT. ANN. tit. 21, § 513(b) (1987). 
  
142 Journal of Legislation [Vol. 45:6] 
statute—the employee is safe from a drug test and an adverse employment action 
based thereon.  
On this point, it important to clarify that employers can test their employees for 
multiple different reasons in most states, even in states that generally prohibit random 
drug testing of employees who are not in safety-sensitive positions.  For example, 
Minnesota law authorizes “[r]outine physical examination testing” and “[t]reatment 
program testing” of current employees in all occupations, in addition to reasonable 
suspicion drug testing.124  The narrow issue this Note discusses here is whether ran-
dom drug testing of employees who are not in safety-sensitive positions in the ordi-
nary course of work is desirable.   
Under Minnesota law, for example, in order to drug test an employee, there must 
be a reasonable suspicion that the employee is under the influence of drugs; has vio-
lated the workplace drug policy; has caused an injury to himself or others; or has 
otherwise caused an accident.125  The Minnesota drug testing statute defines “rea-
sonable suspicion” as “a basis for forming a belief based on specific facts and rational 
inferences drawn from those facts.”126  There is an exception to the general rule for 
employees in a “safety-sensitive position” and qualifying professional athletes.127  
Minnesota law defines “safety-sensitive” jobs as those “in which impairment caused 
by drug or alcohol usage would threaten the health or safety of any person.”128  Al-
lowing random drug testing of employees in safety-sensitive positions accounts for 
the fact that safety is always an employer’s concern and—by the time an employer 
has a reasonable suspicion of employee drug use—it may be too late to avoid harm 
to the employee or others.  
A similar, albeit more refined approach is observable under Connecticut law, 
which goes a step further than Minnesota law in requiring an employer who drug 
tests an employee to have a reasonable suspicion that the employee in question is 
under the influence of drugs that “adversely affects or could adversely affect such 
employee’s job performance.”129  Similarly, there is an exception for employees who 
are in “high-risk or safety-sensitive occupation[s].”130  Vermont’s law takes a nar-
rower tack still by flat-out prohibiting random drug testing “except when such testing 
is required by federal law or regulation.”131 
In the absence of any compelling justification—such as the implication of “the 
health or safety of any person”132—random drug testing interferes with “individual 
autonomy and privacy”133 in a way that is socially undesirable.  In the public sector, 
random drug testing programs that do not require “at least a reasonable suspicion” of 
substance use “have generally been struck down as violative of the [F]ourth 
                                                          
124  MINN. STAT. ANN. § 181.951(4)-(6) (2005).  
125  MINN. STAT. ANN. § 181.951 subd. 4(1)-(4) (2005). 
126  MINN. STAT. ANN. § 181.950(12) (1991).  
127  MINN. STAT. ANN. § 181.951(5) (2005); MINN. STAT. ANN. § 181.951(4) (2005).  
128  MINN. STAT. ANN. § 181.950(13) (1991).  
129  CONN. GEN. STAT. ANN. § 31-51x (2016) (emphasis added). 
130  Id.   
131  VT. STAT. ANN. tit. 21, § 513(b) (1987).  
132  See, e.g., MINN. STAT. ANN. § 181.950(13) (1991).  
133  Rector, supra note 25, at 1070.  
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[A]mendment.”134  While Fourth Amendment protections do not apply to the private 
sector, similar policy concerns do.  Employees should be protected from interference 
with their personal use of legal medication to the utmost extent practicable in the 
modern workplace, at least until their performance is negatively impacted and/or 
workplace safety is threatened.  State laws that require employers to have a reasona-
ble suspicion of drug use before they test their employees—when employee intoxi-
cation would not otherwise pose an immediate health or safety risk—strike the only 
balance that makes sense from a public policy standpoint in the prescription opioid 
context.  As a default, employees who are legitimately taking prescribed opioids to 
promote day-to-day functioning should be trusted to use their best judgment in doing 
so, unless their employer reasonably suspects there is a problem. 
 
E. Mandatory EAP Counseling before Employees may be Terminated 
 
Recognizing that addiction is a mental health issue, providing employees an op-
portunity to course-correct even after receiving a positive drug test result—before 
they are terminated— can help alleviate some of the social costs of employee drug 
use.  Four states with mandatory drug testing guidelines—Maine, Minnesota, Rhode 
Island, and Vermont—require employers to provide employees who fail a drug test 
for the first-time counseling or access to an EAP before they may be terminated.   
In Maine, for example, all employers with over twenty employees must develop 
an EAP and must provide an employee “who receives an initial . . . positive [test] 
result . . . an opportunity to participate for up to six months in a rehabilitation pro-
gram designed to enable the employee to avoid future use of a substance of abuse and 
to participate in an employee assistance program.”135  Similarly, in Rhode Island, 
drug testing is only allowed if “[e]mployees testing positive are not terminated on 
that basis, but are instead referred to a substance abuse professional . . . for assis-
tance.”136  Employees may, however, be terminated for failure to complete said coun-
seling program.137 
 The benefits of an EAP or comparable counseling program in the prescription 
opioid context are manifest.  Importantly, EAP’s can “help identify drug abuse and 
provide confidential access to treatment”138 in a context in which the line between 
prescribed use and problematic use can quickly become blurred by the potency and 
addictive quality of the drugs.  From an employer’s perspective, EAP’s help to pro-
tect the investment in an employee through “training and institutional knowledge” as 
well as potentially realize “positive effects on productivity” by addressing an em-
ployee’s drug use.139  For employees, “robust counseling” may enhance awareness 
                                                          
134  Leland B. Cross & Douglas Craig Hanley, Legal Issues Involved in Private Sector Medical Testing 
of Job Applicants and Employees, 20 IND. L. REV. 517, 520 (1987).  
135  ME. REV. STAT. ANN. tit. 26, § 685(2)(B) (2003); see also ME. REV. STAT. ANN. tit. 26, § 683(1) 
(West 2011); see also MINN. STAT. ANN. § 181.953(b)(1) (West 2004); VT. STAT. ANN. tit. 21, § 513(c)(3) 
(West 1987). 
136  R.I. GEN. LAWS ANN. § 28-6.5-1(a)(3) (West 2013).  
137  See, e.g., VT. STAT. ANN. tit. 21, § 513(c)(3) (West 1987).  
138  Hickox, supra note 24, at 460.   
139  Id.  
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of the risks of opioid use and “may prevent further use from occurring.”140  Most 
importantly, in providing an opportunity for rehabilitation, employers may help avoid 
some of the potential consequences of cutting loose employees suffering from addic-
tion, which can range from counterproductive to utterly tragic.   
There is some controversy as to how these programs should be provided and/or 
financed.  Under Vermont law, for example, “a bona fide rehabilitation program” 
must be provided “by the employer” or be available “to the extent provided by a 
policy of health insurance or under contract by a nonprofit hospital service corpora-
tion.”141  Conversely, under Minnesota law, the employer has a responsibility to pro-
vide an employee who tests positive an opportunity to participate in rehabilitation “at 
the employee’s own expense or pursuant to coverage under an employee benefit 
plan.”142  It is important at the very least, however, that state law require some reha-
bilitation opportunity for first-time offenders of workplace drug policies.  Providing 
rehabilitation opportunities helps to protect employers’ investments in human capital 
and promotes the broader social goal of remedying the adverse effects of the pre-
scription opioid epidemic, rather than handing off the problem to other employers or 
to society at large.   
 
F. Private Right of Action for Employers’ Failure to Comply with the Statute 
 
The existence of a mandatory drug testing law is all fine and well, but the ques-
tion is, what happens to an adversely affected employee when his or her employer 
fails to live up to its end of the bargain?  Seven of the states with mandatory drug 
testing guidelines as discussed above—Connecticut, Hawaii, Maine, Minnesota, Ok-
lahoma, Rhode Island, and Vermont—provide a private right of action for violations 
of their respective statutes.143  Another three states—Iowa, Louisiana, and Utah—
only provide a private right of action for a false positive test result.144  Uniquely, in 
Rhode Island, an employee may be able to obtain punitive damages for a successful 
claim against an employer in violation of the applicable statute.145   
Admittedly, from an employer’s perspective, the availability of a private right of 
action is not good news.  Obviously, this opens employers up to potential liability.  
From the perspective of an employee, however, a private right of action is critical in 
that it gives some teeth to her concerns, which would otherwise be largely subverted 
to the concerns of her employer under the prevailing doctrine of employment-at-will.  
Although available in only a small minority of jurisdictions, such a provision is cru-
cial to advancing the public policy issues raised throughout this Note.  The threat of 
                                                          
140  Foulke & Vance, supra note 59.  
141  VT. STAT. ANN. tit. 21, § 513 (1987). 
142  MINN. STAT. ANN. § 181.953(10)(b)(1) (2004).  
143  See CONN. GEN. STAT. ANN. § 31-51z (West 1987); HAW. REV. STAT. ANN. § 329B-7 (West 
1990); ME. REV. STAT. ANN. tit. 26, § 689(1) (1989); MINN. STAT. ANN. § 181.956 (West 1987); OKLA. 
STAT. ANN. tit. 40, § 563 (West 2011); R.I. GEN. LAWS ANN. § 28-6.5-1(c) (West 2013); VT. STAT. ANN. tit. 
21, § 519 (West 1987). 
144  See IOWA CODE ANN. § 730.5(12)(a) (West 2017); LA. STAT. ANN. § 49:1012(B) (1990); UTAH 
CODE ANN. § 34-38-10 (West 2010). 
145  R.I. GEN. LAWS ANN. § 28-6.5-1(c)(1) (West 2013). 
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a private right of action can help motivate employer compliance with state drug test-
ing laws, with the result of reducing litigious conflict overall.  Furthermore, by giving 
employees a litigatory weapon, the playing field with their employers is closer to 
level; this balance will promote trust and cooperation rather than suspicion and fear.  
The more positive the interaction between employer and employee, the more likely 
they are to resolve the conflict ex ante, without having to invoke the private right of 
action—and resort to litigation—at all.   
 
 




















Connecticut  X146  X147  X148 
Hawaii  X149 X150   X151 
Iowa X152 X153 X154   X155 
Louisiana X156  X157   X158 
                                                          
146 CONN. GEN. STAT. ANN. § 31-51u(a) (West 1995) (“No employer may (take an adverse employ-
ment action) solely on the basis of a positive urinalysis drug test unless . . . such positive test was confirmed 
by a second urinalysis drug test.”).  
147 See CONN. GEN. STAT. ANN. § 31-51x (West 2016). 
148  CONN. GEN. STAT. ANN. § 31-51z (West 1987) (“Any aggrieved person may enforce the provisions 
of (this statute) by means of a civil action.”).  
149  See HAW. REV. STAT. ANN. § 329B-5.5(2) (West 2007). 
150  See HAW. REV. STAT. ANN. § 329B-2 (West 2001) (“‘Medical review officer’ means an individual 
who has knowledge of substance abuse disorders and toxicology as determined by the department, and is ap-
pointed by the third party to receive, review, and interpret the results of laboratory tests requested by the third 
party.”).  
151  See HAW. REV. STAT. ANN. § 329B-7 (West 1990). 
152  IOWA STAT. ANN. § 730.5(7)(c)(2) (West 2017) (“An employee or prospective employee shall be 
provided an opportunity to provide any information which may be considered relevant to the test, including 
identification of prescription or nonprescription drugs currently or recently used, or other relevant medical 
information.”).  
153  IOWA CODE ANN. § 730.5(7)(f)(1), (2) (West 2017) (“Drug or alcohol testing shall include confir-
mation of any initial positive test result.”).  
154  See IOWA CODE ANN. § 730.5(7)(g) (West 2017) (“‘Medical review officer’ means a licensed phy-
sician, osteopathic physician, chiropractor, nurse practitioner, or physician assistant authorized to practice in 
any state of the United States, who is responsible for receiving laboratory results generated by an employer's 
drug or alcohol testing program.”).  
155  See IOWA CODE ANN. § 730.5(12)(a) (West 2017).  
156  See LA. STAT. ANN. § 49:1005(B) (2015); see also Mandatory Guidelines for Federal Workplace 
Drug Testing Programs, 80 Fed. Reg. 94, 28101, 94, 28105 (May 15, 2015), 
https://www.gpo.gov/fdsys/pkg/FR-2015-05-15/pdf/2015-11524.pdf (“Consistent with the current (SAM-
HSA) Guidelines, the MRO must contact the donor to determine if there is a legitimate medical explanation 
(e.g., a valid prescription) for the positive result.”).  
157  LA. STAT. ANN. § 49:1001(5) (2015) (“‘Medical review officer’ means a licensed physician respon-
sible for receiving laboratory results generated by employer.”).  
158  See LA. STAT. ANN. § 49:1012(B) (1990). 
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Maine X159 X160   X161 X162 
Maryland X163 X164 X165    
Minnesota X166 X 167  X168 X169 X170 
Montana X171 X 172 X173    
Nebraska  X174     
Oklahoma  X175 X176   X177 
                                                          
159  ME. REV. STAT. ANN. tit. 26, § 683(8)(B) (West 2012) (“Within 3 working days after notice of a 
confirmed positive test result, the employee or applicant may submit information to the employer explaining 
or contesting the results.”).  
160  ME. REV. STAT. ANN. tit. 26, § 683(7) (West 2003) (“If a screening test result is positive, a confir-
mation test shall be performed on that sample.”).  
161  ME. REV. STAT. ANN. tit. 26, § 685(2)(B) (West 2003); see also ME. REV. STAT. ANN. TIT. 26, § 
683(1) (West 2011) (“Before taking (any adverse employment action) in the case of an employee who re-
ceives an initial confirmed positive result, an employer shall provide the employee with an opportunity to par-
ticipate for up to 6 months in a rehabilitation program designed to enable the employee to avoid future use of 
a substance of abuse and to participate in an employee assistance program, if the employer has such a pro-
gram.”).  
162  See ME. REV. STAT. ANN. tit. 26, § 689(1) (West 1989). 
163  MD. COD ANN., HEALTH-GEN. § 17-214(i)(3) (West 2017) (explaining that “if the preliminary test 
is positive, the applicant may voluntarily disclose and provide documentation to the operator that the applicant 
is taking a legally prescribed medication”).  
164  MD. CODE ANN., HEALTH-GEN § 17-214(j)(1) (West 2017) (“An employer using preliminary 
screening procedures to test job applicants under this section shall have a medical review officer review a pos-
itive test result after laboratory confirmation of the positive test result.”).  
165  MD. CODE ANN., HEALTH-GEN § 17-214(a)(8) (West 2017) (“‘Medical review officer’ means a 
licensed physician with knowledge of drug abuse disorders and drug and alcohol testing.”).  
166  MINN. STAT. ANN. § 181.953(6)(b) (West 2004) (“If an employee or job applicant tests positive for 
drug use, the employee must be given written notice of the right to explain the positive test and the employer 
may request that the employee or job applicant indicate any over-the-counter or prescription medication that 
the individual is currently taking or has recently taken and any other information relevant to the reliability of, 
or explanation for, a positive test result.”).  
167  MINN. STAT. ANN. § 181.953(3) (West 2004) (“A testing laboratory shall conduct a confirmatory 
test on all samples that produced a positive test result on an initial screening test.”).  
168  See MINN. STAT. ANN. § 181.951(4) (West 2005); see also MINN. STAT. ANN. § 181.951(5) (West 
2005). 
169  MINN. STAT. ANN. § 181.953(10)(b) (West 2004) (“[A]n employer may not discharge an employee 
for whom a positive test result on a confirmatory test was the first such result for the employee on a drug or 
alcohol test requested by the employer unless . . . the employer has first given the employee an opportunity to 
participate in … either a drug or alcohol counseling or rehabilitation program . . . and . . . the employee has 
either refused to participate in the counseling or rehabilitation program or has failed to successfully complete 
the program.”).  
170  See MINN. STAT. ANN. § 181.956 (West 1987).  
171  MONT. CODE ANN. § 39-2-207(5) (West 2005) (“An employee or prospective employee must be 
given the opportunity to provide information to the medical review officer of any medical information that is 
relevant to interpreting test results.”).  
172  See MONT. CODE ANN. § 39-2-207(4) (West 2005).  
173  MONT. CODE ANN. § 39-2-207(5) (West 2005) (“Before an employer may take any action based on 
a positive test result, the employer shall have the results reviewed and certified by a medical review officer 
who is trained in the field of substance abuse.”).  
174  See NEB. REV. STAT. ANN. § 48-1903 (West 2000). 
175  See OKLA. STAT. ANN. tit. 40, § 559(8) (West 1993).  
176  See OKLA. STAT. ANN. tit. 40, § 552(11) (West 2012).  
177  See OKLA. STAT. ANN. tit. 40, § 563 (West 2011).   
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Rhode Is-
land X
178 X179  X180 X181 X182 
Utah X183 X184    X185 
Vermont  X186 X187 X188 X 189 X190 
 
Based on the foregoing table and criteria described therein, Minnesota, Rhode 
Island and Vermont have particularly robust workplace drug testing laws insofar as 
they endeavor to strike the balance between employer and employee interests related 
to prescription opioid use.  In particular, these state laws have incorporated most of 
the six factors identified supra and can therefore serve as a model for other states 
endeavoring to find a solution to the prescription opioid problem, as it manifests itself 
in the workplace. 
But even these laws—exemplary as they are—are not without their critics.  A 
brief explanation of their shortcomings can advance the discussion even further by 
showing how even the best can improve, and why state policymakers may not want 
to stop at merely copying others.   
For example, Minnesota’s Drug and Alcohol Testing in the Workplace Act 
(DATWA) has been criticized as “too complicated and burdensome” and “a trap for 
unwary employers,” even after extensive clarification by the Minnesota courts.191  
Minnesota’s DATWA may provide an example of a law that—in providing substan-
tial protection for employees—may have overreached the goal in failing to establish 
clear rights and guidelines for employees and their employers, so as to avoid conflict 
by clarifying the expectations of both parties ex ante.  
The fact that Minnesota was a crusader in workplace drug testing laws also high-
lights a potential issue; DATWA has been around for thirty years but has “not kept 
up with the modern science of drug and alcohol testing when it comes to collection, 
laboratory, and MRO procedures.”192  A simple way to promote uniformity in the 
law, ensure procedural protections for employees, and reduce employer confusion 
would be to conform DATWA’s drug testing procedures to those found in the De-
partment of Transportation’s (DOT) guidelines for the transportation industry.193   
                                                          
178  28 R.I. GEN. LAWS ANN. § 28-6.5-1(a)(6) (West 2013) (“Employers may require that an employee 
submit to a drug test if . . . [t]he employer provides the test to the employee with a reasonable opportunity to 
rebut or explain the results.”).  
179  See 28 R.I. GEN. LAWS ANN. § 28-6.5-1(a)(4) (West 2013).  
180  See 28 R.I. GEN. LAWS ANN. § 28-6.5-1(a)(1) (West 2013).  
181  See 28 R.I. GEN. LAWS ANN. § 28-6.5-1(a)(3) (West 2013).  
182  See 28 R.I. GEN. LAWS ANN. § 28-6.5-1(c) (West 2013).   
183  See UTAH CODE ANN. § 34-38-6(4) (West 2010). 
184  See UTAH CODE ANN. § 34-38-6-(6) (West 2010).  
185  See UTAH CODE ANN. § 34-38-10 (West 2010).  
186  See VT. STAT. ANN. tit. 21, § 514(6) (West 2001).  
187  See VT. STAT. ANN. tit. 21, § 514(11) (West 2001).  
188  See VT. STAT. ANN. tit. 21, § 513(c)(1) (West 1987).  
189  See VT. STAT. ANN. tit. 21, § 513(c)(3) (West 1987).  
190  See VT. STAT. ANN. tit. 21, § 519 (West 1987).  
191  Ella & Trepanier, supra note 7, at 18.  
192  Id. 
193  Id. See 49 C.F.R. § 40 (2000), https://www.ecfr.gov/cgi-bin/text-
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Similarly, Rhode Island’s law is considered a minefield for employers because 
of the severe restrictions on workplace drug testing that it imposes and the conse-
quences of noncompliance.  As one commentator has advised, “[u]nless your com-
pany is subject to statutory or other requirements to test workers for illegal drug use, 
we don’t recommend drug testing employees in Rhode Island.”194  This should not 
be the goal of mandatory state drug testing guidelines because employers have legit-
imate concerns in workplace safety and productivity that ideally should be protected, 
as well as employee interests.  Thus, Rhode Island legislators, like those in Minne-
sota, may need to reevaluate the system created by the law in order to strike a better, 
more sensitive balance between these competing interests.  
Vermont—another crusader—may, like Minnesota, have failed to adapt to the 
modern workplace.  Unlike Minnesota law, however, Vermont law may benefit from 
being more employee-friendly still.  Although Vermont’s workplace drug testing law 
was “innovative” at the time of its passage in 1987, commentators urge that “useful 
reevaluation of Vermont’s law is feasible” given the “benefit of seeing what . . . other 
states have done” in terms of regulating private sector workplace drug testing.195  
Specifically, Field urged in his 1989 article that Vermont’s “legislative balance be-
tween the needs of employers and the privacy rights of employees … should be tilted 
even further in favor of the latter group.”196  As Field explains, a legislative response 
is necessary to improve the law because “it is extremely unlikely that Vermont em-
ployers who currently have drug testing programs will take the initiative [to adopt 
employee-friendly provisions] in the absence of legislative change.”197 
Field additionally recommended that Vermont adopt a “unique protection” avail-
able under Utah law that requires employers and managers to “submit to the testing 
themselves on a periodic basis.”198  Such a provision certainly would promote a dem-
ocratic and progressive approach to workplace drug testing, thereby further eroding 
employment-at-will in this context.  Field also recommended that the “probable 
cause” standard for drug testing under Vermont law199 be heightened to the standard 
set under Rhode Island and Iowa law, which requires an employer’s belief that an 
employee’s abilities are actually impaired.200  This is slightly more nuanced than the 
                                                          
idx?SID=44edbc0e557a4cc5ff03365810ee5b1c&mc=true&node=pt49.1.40&rgn=div5; see also 
https://www.transportation.gov/sites/dot.dev/files/docs/ODAPC_EmployeesCoveredUnderDOTTestingRegu-
lation49CFRPart40.pdf (providing a summary of employees covered by the DOT regulations).  Currently, un-
der Minnesota law, threshold levels advanced by SAMHSA, the College of American Pathologists (CAP), or 
the New York State Department of Health (NYSDH) may sustain a positive test result.  CAP and NYSDH 
provide significantly lower metabolite threshold levels than the DOT, which may promote confusion and lead 
to adverse employment decisions based on positive drug test results that are not necessarily desirable for em-
ployees or employers. See Ella & Trepanier, supra note 7, at 16.  
194  Meghan E. Siket, No Individual Liability Under Rhode Island Drug Testing Law, 18 No. 8 R.I. 
EMP. L. LETTER 2 (2013).  
195 Andrew J. Field, Jar Wars in the Green Mountain State: Vermont’s Drug Testing Act Has the Po-
tential to be the Best in the Nation, 13 VT. L. REV. 593, 594 (1989).  
196  Id.  
197  Id. at 607.  
198  Id. at 605.  
199  See VT. STAT. ANN. tit. 21, § 513(c)(1) (1987).  
200  Field, supra note 195, at 604.  
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point made earlier in this Note generally favoring some level of reasonable suspi-
cion—rather than random—drug testing of employees in non-safety-sensitive posi-
tions.  Field’s test would narrow the testing requirement further still to the “point 
where employees’ drug use, by interfering with job performance, gives rise to the 
employer’s need to test for drugs in order to decrease the related production costs.”201  
In sum, even those state laws that are the best equipped to address the problems 
raised by the prescription opioid epidemic could also be tailored further to that end.  
Times change, and new eras present new issues—and new problem drugs—that em-
ployers must deal with.  In turn, the law must also be adaptive, so as to best meet the 
needs of employers, employees, and society at large at any given point in time, de-




In an ideal world, employers would not drug test their employees in the absence 
of legitimate concerns about workplace safety and productivity.  In electing to drug 
test, employers would develop workplace drug policies that are both fair and clearly 
communicated to their employees.  Likewise, employees would not abuse their em-
ployers’ trust and would respect their employers’ workplace policies because they 
understand the role those policies played in promoting a safe and efficient workplace.  
They would not contest those policies because those policies do not unnecessarily 
interfere with their personal lives and medical needs.  
Unfortunately, as the statistics on the prescription opioid epidemic indicate, we 
do not live in an ideal world.  Employers are wary of the enormous potential costs of 
prescription opioid use by their employees, and employees are wary of employers 
who generally have broad discretion to test and terminate.  Meaningful communica-
tion and accommodation seem to have fallen by the wayside, to the detriment of both 
interest groups as well as society at large.  The potential for conflict is abundant, and 
while different parties may prevail under different circumstances on different days, 
it is clear that at least some conflict could be avoided entirely by clarifying expecta-
tions ex ante.  
Recognizing that both the employer and employee have legitimate concerns that 
may be difficult to balance without guidance, state law has the potential to play an 
important role in this regard.  Employers historically have had the bulk of the power 
and—faced with the new threat of the prescription opioid epidemic—may be unwill-
ing to bargain any of it away.  In an environment of distrust, employees are likely to 
be uncooperative and leap at the opportunity to sue.  Thus, state law can further over-
all social goals by restoring trust, guaranteeing fair procedures for employees, provid-
ing employees with substance abuse problems access to help, and providing employ-
ees a mechanism to seek redress when employers do not hold up their end of the 
bargain.  At the other end of the spectrum, policymakers must remain cognizant of 
the risk that workplace drug testing laws may become overprotective or too compli-
cated and undermine the very social goals they were enacted to accomplish.    
In sum, the perfect balance is a sensitive one.  But in light of the fact that so few 
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states have mandatory drug testing guidelines to begin with, there is certainly oppor-
tunity for improvement in the protections that state law affords employer and em-
ployee interests in this context across the board.  Mandatory state drug testing guide-
lines with the key provisions discussed in Part III, supra of this Note model a 
progressive approach to drug testing in the workplace in the age of prescription opi-
oids.  States that have not yet implemented such laws should consider doing so, look-
ing for inspiration in the laws of Minnesota, Rhode Island, and Vermont, among oth-
ers.  States with workplace drug testing laws already in place should reevaluate their 
chosen approaches in order to account for the unique challenges raised by the pre-
scription opioid epidemic in the American workplace, as its effects are realized over 
time.   
 
 
 
 
